DNUT:NASDAQKrispy Kreme, Inc. Analysis
Data as of 2026-03-29 - not real-time
$3.23
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Krispy Kreme’s stock is trading at $3.23, just above the computed support level of $3.135 and well below the resistance of $3.79, indicating limited upside in the near term. The 20‑day SMA ($3.456) sits above the 50‑day SMA ($3.314) but remains under the 200‑day SMA ($3.563), a mixed signal that aligns with the neutral trend direction. Momentum indicators are tepid: the RSI is 44, suggesting the stock is neither overbought nor oversold, while the MACD histogram is negative and flagged as bearish. Volatility is high at roughly 90% over the past 30 days and beta exceeds 1.0, pointing to a stock that swings sharply with the market. Fundamentally, the company carries a heavy debt load (debt‑to‑equity > 200) and negative profitability metrics (‑34.9% profit margin, negative EPS), yet it trades at a low price‑to‑book of 0.85 and price‑to‑sales of 0.36, which could be interpreted as a discount. The dividend yield appears attractive at 4.33%, but with negative earnings and a payout ratio of 7%, sustainability is doubtful.
Recent material news highlights a turnaround narrative: Q4 results beat estimates, guidance for 2026 was raised, and a new OREO doughnut collection sparked a 23.8% 7‑day price rally and a 19.0% 30‑day gain. A $120 million cash infusion from recent transactions strengthens the balance sheet and supports a capital‑light refranchising strategy aimed at international growth. While the short‑term price momentum is encouraging, the lingering leverage and earnings challenges keep risk elevated, suggesting a cautious but potentially rewarding investment horizon.
Recent material news highlights a turnaround narrative: Q4 results beat estimates, guidance for 2026 was raised, and a new OREO doughnut collection sparked a 23.8% 7‑day price rally and a 19.0% 30‑day gain. A $120 million cash infusion from recent transactions strengthens the balance sheet and supports a capital‑light refranchising strategy aimed at international growth. While the short‑term price momentum is encouraging, the lingering leverage and earnings challenges keep risk elevated, suggesting a cautious but potentially rewarding investment horizon.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near technical support with limited immediate upside
- High short‑term volatility and bearish MACD
- Recent 7‑day rally may be short‑lived
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Turnaround momentum and raised guidance
- Capital‑light refranchising and international revenue upside
- Attractive valuation multiples relative to book and sales
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Heavy debt burden and negative free cash flow
- Uncertain dividend sustainability
- Brand strength and potential for gradual international expansion
Key Metrics & Analysis
Financial Health
Revenue Growth-2.90%
Profit Margin-33.87%
P/E Ratio-40.0
ROE-56.89%
ROA-1.33%
Debt/Equity211.73
P/B Ratio0.9
Op. Cash Flow$33.9M
Free Cash Flow$-61717500
Technical Analysis
TrendNeutral
RSI44.1
Support$3.13
Resistance$3.79
MA 20$3.46
MA 50$3.31
MA 200$3.56
MACDBearish
VolumeStable
Fear & Greed Index65.98
Valuation
Target Price$4.35
Upside/Downside34.67%
GradeUndervalued
TypeBlend
Dividend Yield4.33%
Risk Assessment
Beta1.11
Volatility89.59%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.